Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide We report the optimization of a series of IRAK1/4/pan-FLT3 kinase inhibitors. These efforts have produced a key compound 27 that displays potent and selective inhibition of IRAK1, IRAK4, and FLT3, reduced block of hERG, and good pharmacokinetic properties. In a mouse xenograft model of acute myeloid leukemia (AML), 27 produces survival prolongation superior to that of gilteritinib, the leading FDA-approved FLT3 inhibitor currently used to treat AML.
No takes yet. Share an insight, caveat, or question.
Hoyt et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: